To include your compound in the COVID-19 Resource Center, submit it here.

SNS01-T: Completed Phase Ib/IIa enrollment

Sevion (formerly Senesco Therapeutics Inc.) completed enrollment in an open-label, dose-escalation, U.S. Phase Ib/IIa trial evaluating 0.0125, 0.05, 0.2

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE